LabCentral
Residency at LabCentral
As a leader in neuroscience and rare disease, Biogen seeks to engage with those who are championing revolutionary ideas in multiple areas of neuroscience as well as the next generation of drug discovery technologies and platforms.
External Innovation Unit
The External Innovation Unit represents Biogen by establishing a global network with industry, academia and others to foster external collaborations, driving innovation while strengthening the neuroscience ecosystem.
LabCentral
LabCentral is a first-of-its-kind, shared laboratory space designed to launch life science and biotech start-ups. LabCentral provides the infrastructure entrepreneurs and innovators need to test out, challenge and nurture their ideas.
As a platinum sponsor, Biogen’s External Innovation Unit can nominate up to two early-stage companies each year to take up residence in LabCentral's Kendall Square facilities. Each Biogen-LabCentral Golden Ticket includes The Golden Ticket value of $50K credit for space at LabCentral 700 to be used within 13 months of issue and the benefits of LabCentral's shared infrastructure and services at no cost to the contest winner. See https://www.labcentral.org/our-labs/labcentral-700.
Special consideration will be provided to proposals focused on neuroscience, neurodegeneration and areas related to Biogen research.
Competition Rules, Eligibility and Judging Criteria
Applicants for the Biogen-LabCentral Golden Ticket Competition will need to submit an application following the link below. More information can be found under Eligibility criteria, terms and conditions.
Last year’s winners of Biogen Golden Tickets were: Cerberus Therapeutics and Transcera.
Companies meeting the eligibility criteria can submit an application following the link below including a brief non-confidential proposal by 11:59 PM, Eastern Time, on November 15th.
Contact
Paul Andrews
Senior Director, External Innovation
Biogen | 225 Binney Street | Cambridge, MA | 02142